As of 2025-11-05, the EV/EBITDA ratio of Theravance Biopharma Inc (TBPH) is -14.58. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TBPH's latest enterprise value is 435.65 mil USD. TBPH's TTM EBITDA according to its financial statements is -29.87 mil USD. Dividing these 2 quantities gives us the above TBPH EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 4.3x - 8.6x | 5.0x |
| Forward P/E multiples | 5.6x - 6.3x | 5.8x |
| Fair Price | 2.78 - 2.39 | 2.93 |
| Upside | -81.2% - -83.8% | -80.2% |
| Date | EV/EBITDA |
| 2025-11-04 | -14.58 |
| 2025-11-03 | -15.38 |
| 2025-10-31 | -14.43 |
| 2025-10-30 | -13.82 |
| 2025-10-29 | -13.61 |
| 2025-10-28 | -13.49 |
| 2025-10-27 | -13.82 |
| 2025-10-24 | -13.79 |
| 2025-10-23 | -13.55 |
| 2025-10-22 | -13.32 |
| 2025-10-21 | -13.34 |
| 2025-10-20 | -13.84 |
| 2025-10-17 | -13.76 |
| 2025-10-16 | -13.39 |
| 2025-10-15 | -13.15 |
| 2025-10-14 | -13.07 |
| 2025-10-13 | -13.18 |
| 2025-10-10 | -13.30 |
| 2025-10-09 | -14.18 |
| 2025-10-08 | -14.06 |
| 2025-10-07 | -13.91 |
| 2025-10-06 | -14.30 |
| 2025-10-03 | -14.01 |
| 2025-10-02 | -13.44 |
| 2025-10-01 | -14.03 |
| 2025-09-30 | -14.33 |
| 2025-09-29 | -14.04 |
| 2025-09-26 | -13.44 |
| 2025-09-25 | -12.96 |
| 2025-09-24 | -13.40 |
| 2025-09-23 | -13.44 |
| 2025-09-22 | -13.44 |
| 2025-09-19 | -13.12 |
| 2025-09-18 | -14.11 |
| 2025-09-17 | -13.40 |
| 2025-09-16 | -13.10 |
| 2025-09-15 | -13.99 |
| 2025-09-12 | -13.82 |
| 2025-09-11 | -12.81 |
| 2025-09-10 | -12.71 |
| 2025-09-09 | -12.91 |
| 2025-09-08 | -13.18 |
| 2025-09-05 | -13.23 |
| 2025-09-04 | -13.40 |
| 2025-09-03 | -12.87 |
| 2025-09-02 | -13.05 |
| 2025-08-29 | -13.12 |
| 2025-08-28 | -13.27 |
| 2025-08-27 | -12.98 |
| 2025-08-26 | -12.98 |